VEGFA and hereditary elliptocytosis: Although our study participants were all patients with high-risk PDR, their blood glucose control and disease progress were not used to classify the location of HE and NV within the groups, which may have led to inconsistent responses to anti-VEGF drugs and, thus, affected the prognosis of retinal anatomical structure and function.